More about

Major Depressive Disorder

News
August 24, 2022
2 min read
Save

Higher dose of omega-3 fatty acid reduced MDD in overweight adults at 12 weeks

Higher dose of omega-3 fatty acid reduced MDD in overweight adults at 12 weeks

Eicosapentaenoic acid at a dose of 4 g per day reduced effects of major depressive disorder in overweight individuals with elevated inflammatory markers better than placebo at 12 weeks, according to a recently published study.

News
July 21, 2022
1 min read
Save

FDA provides guidance to Alzamend ahead of IND application for oral therapeutic

FDA provides guidance to Alzamend ahead of IND application for oral therapeutic

The FDA has provided guidance to biopharmaceutical company Alzamend Neuro Inc. regarding its development of an oral therapeutic to treat a range of psychological disorders.

News
July 13, 2022
1 min read
Save

Psilocybin for MDD clinical trial begins enrollment

Psilocybin for MDD clinical trial begins enrollment

Clinilabs Drug Development Corp. announced enrollment has begun in a phase 1/2a clinical trial for the use of CYB003, a novel psilocybin analog that will be evaluated for the treatment of major depressive disorder.

News
July 06, 2022
2 min read
Save

Dextromethorphan-bupropion effective in improving symptoms of major depressive disorder

Dextromethorphan-bupropion effective in improving symptoms of major depressive disorder

Dextromethorphan-bupropion significantly improved symptoms for those with major depressive disorder compared with bupropion alone and produced minimal adverse effects, according to a study published in American Journal of Psychiatry.

News
June 07, 2022
2 min watch
Save

VIDEO: Adjunctive treatment with cariprazine improved depression symptoms

VIDEO: Adjunctive treatment with cariprazine improved depression symptoms

NEW ORLEANS – Patients who received cariprazine in addition to their standard antidepressant showed clinical improvement for depression, Gary Sachs, MD, said at the American Psychiatric Association annual meeting.

News
May 10, 2022
1 min read
Save

FDA approves TMS as form of OCD treatment

FDA approves TMS as form of OCD treatment

The FDA has approved Neuronetics’ transcranial magnetic stimulation system, called NeuroStar, as an adjunct treatment for adults with obsessive compulsive disorder.

News
May 04, 2022
1 min read
Save

Psilocybin-assisted treatment for depression safe, effective through 12 months

Psilocybin-assisted treatment for depression safe, effective through 12 months

Through 12 months, psilocybin-assisted treatment showed to be safe and effective for major depressive disorder, researchers reported in the Journal of Psychopharmacology.

News
May 02, 2022
1 min read
Save

Rolling submission of NDA begins for FDA on daily oral drug for depression

Rolling submission of NDA begins for FDA on daily oral drug for depression

Sage Therapeutics and Biogen Inc. announced they have initiated a rolling submission for a New Drug Application to the FDA for zuranolone, a once-daily oral drug being developed to treat major depressive disorder.

News
April 27, 2022
1 min read
Save

Digital therapeutic tool improved attention, cognitive function for adults with MDD

Digital therapeutic tool improved attention, cognitive function for adults with MDD

Use of a digital therapeutic tool by adults with major depressive disorder resulted in significant improvement in attention and cognitive functioning, according to a study published in the American Journal of Psychiatry.

News
April 13, 2022
1 min read
Save

Comorbidities linked to treatment-resistant depression in older adults with MDD

Comorbidities linked to treatment-resistant depression in older adults with MDD

Older adults with late-onset major depressive disorder and anxiety or substance use disorders were more likely to experience treatment-resistant depression, a study published in the Journal of Clinical Psychiatry showed.

View more